Floatz logo

Olvimulogene Nanivacirepvec

Ovarian Clear Cell Carcinoma

Genelux Corporationgene_therapyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Ovarian Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
Genelux Corporation
Phase 3BB
Carboplatin
Genelux Corporation
Phase 3BB
Docetaxel
Genelux Corporation
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3B
Enmd-2076
University Health Network, Toronto
Phase 2B

View all 20 →

Same molecule, other indications

Olvimulogene Nanivacirepvec is also rated in:

ovarian serous adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Platinum-refractory Ovarian CancerDormant
B
Indicative ·
60 / 100
View asset →
ovarian endometrioid adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →